About Inomagen
Inomagen is a company based in Chicago (United States) founded in 2021.. Inomagen has raised $340 thousand across 4 funding rounds from investors including HHS and NIH SBIR/STTR. Inomagen offers products and services including Gene Therapy Platform. Inomagen operates in a competitive market with competitors including Acesion Pharma, Thryv Therapeutics, MITEM Pharma, Blue Ash Therapeutics and Rhythm Therapeutics, among others.
- Headquarter Chicago, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$340 K (USD)
in 4 rounds
-
Latest Funding Round
$140 K (USD), Seed
Jun 05, 2025
-
Investors
HHS
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Inomagen
Inomagen offers a comprehensive portfolio of products and services, including Gene Therapy Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops non-viral treatments for atrial fibrillation root causes
Funding Insights of Inomagen
Inomagen has successfully raised a total of $340K across 4 strategic funding rounds. The most recent funding activity was a Seed round of $140 thousand completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Seed — $140,000
-
First Round
First Round
(01 May 2021)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2025 | Amount | Seed - Inomagen | Valuation |
investors |
|
| Mar, 2024 | Amount | Seed - Inomagen | Valuation |
investors |
|
| Mar, 2022 | Amount | Grant - Inomagen | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Inomagen
Inomagen has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS and NIH SBIR/STTR. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Inomagen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Inomagen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Inomagen Comparisons
Competitors of Inomagen
Inomagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Acesion Pharma, Thryv Therapeutics, MITEM Pharma, Blue Ash Therapeutics and Rhythm Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drugs for atrial fibrillation are developed targeting SK ion channels.
|
|
| domain | founded_year | HQ Location |
Provider of therapy services for rare diseases
|
|
| domain | founded_year | HQ Location |
Targeted therapies for multiple diseases are developed.
|
|
| domain | founded_year | HQ Location |
Develops innovative drugs targeted at treating cardiovascular disorders.
|
|
| domain | founded_year | HQ Location |
Gene therapy for atrial fibrillation is developed in preclinical stage.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Inomagen
Frequently Asked Questions about Inomagen
When was Inomagen founded?
Inomagen was founded in 2021.
Where is Inomagen located?
Inomagen is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Who is the current CEO of Inomagen?
Rishi Arora is the current CEO of Inomagen.
Is Inomagen a funded company?
Inomagen is a funded company, having raised a total of $340K across 4 funding rounds to date. The company's 1st funding round was a Grant of $1.64M, raised on May 01, 2021.
What does Inomagen do?
Inomagen was founded in 2021 in Chicago, United States, as a biotechnology firm focused on gene therapy for cardiovascular conditions. Therapeutic transgenes are delivered via electroporation to target molecular mechanisms in diseases such as atrial fibrillation. Operations center on research and development of these treatments, with activities conducted primarily in the United States to address serious cardiac disorders.
Who are the top competitors of Inomagen?
Inomagen's top competitors include Acesion Pharma, Thryv Therapeutics and MITEM Pharma.
What products or services does Inomagen offer?
Inomagen offers Gene Therapy Platform.
Who are Inomagen's investors?
Inomagen has 2 investors. Key investors include HHS, and NIH SBIR/STTR.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.